Summary
This comprehensive narrative review, published in Signal Transduction and Targeted Therapy in 2025, synthesises current understanding of VEGF signalling from molecular mechanisms through to clinical application. It covers the roles of VEGF family members and their receptors in angiogenesis, tumour vascularisation, and other disease states, and critically appraises therapeutic approaches including anti-VEGF biologics and small molecule inhibitors. The review is likely intended to serve as a reference framework for researchers and clinicians working on vascular biology and targeted therapy development.
UK applicability
The findings are broadly applicable to UK clinical and research contexts, as anti-VEGF therapies are widely used within NHS oncology and ophthalmology services; the review's therapeutic perspectives may inform UK prescribing guidelines and future trial design.
Key measures
VEGF pathway components and receptor interactions; disease association evidence; therapeutic agent efficacy and safety profiles from cited clinical and preclinical studies
Outcomes reported
The review examines the molecular mechanisms underlying vascular endothelial growth factor (VEGF) signalling and its roles in physiological and pathological contexts, including cancer, cardiovascular disease, and ocular conditions. It likely evaluates existing and emerging therapeutic strategies targeting the VEGF pathway.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.